{"id":67916,"date":"2026-06-10T20:40:24","date_gmt":"2026-06-10T12:40:24","guid":{"rendered":"https:\/\/flcube.com\/?p=67916"},"modified":"2026-06-10T20:40:25","modified_gmt":"2026-06-10T12:40:25","slug":"chinas-four-health-regulators-issue-revised-good-clinical-practice-guidelines-effective-september-2026-strengthening-trial-oversight-and-ethical-standards","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67916","title":{"rendered":"China&#8217;s Four Health Regulators Issue Revised Good Clinical Practice Guidelines Effective September 2026, Strengthening Trial Oversight and Ethical Standards"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong>, <strong>National Health Commission (NHC)<\/strong>, <strong>National Administration of Traditional Chinese Medicine<\/strong>, and <strong>National Disease Control and Prevention Administration<\/strong> jointly released the revised <strong>&#8220;Announcement on the Good Clinical Practice for Drug Trials,&#8221;<\/strong> which will take effect on <strong>September 1, 2026<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The updated guidelines represent a comprehensive modernization of China&#8217;s <strong>2020 Good Clinical Practice (GCP)<\/strong> framework, incorporating <strong>global advancements in clinical trial technology<\/strong> and <strong>evolving international standards<\/strong> while reflecting lessons learned from domestic clinical trial experience. The revisions establish clearer accountability structures and enhanced ethical oversight mechanisms for drug development in China.<\/p>\n\n\n\n<h2 id=\"h-regulatory-framework-amp-key-revisions\" class=\"wp-block-heading\">Regulatory Framework &amp; Key Revisions<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Previous Standard<\/th><th>Revised Requirements<\/th><\/tr><\/thead><tbody><tr><td><strong>Principal Investigator Responsibility<\/strong><\/td><td>General oversight<\/td><td><strong>Ultimate responsibility<\/strong> for all trial conduct at clinical site<\/td><\/tr><tr><td><strong>Sponsor Accountability<\/strong><\/td><td>Delegated oversight<\/td><td><strong>Ultimate responsibility<\/strong> for all trial-related activities<\/td><\/tr><tr><td><strong>Delegation Authority<\/strong><\/td><td>Implicit acceptance<\/td><td><strong>Explicit accountability<\/strong> retained for all delegated\/authorized activities<\/td><\/tr><tr><td><strong>Ethics Committee Role<\/strong><\/td><td>Standard review<\/td><td><strong>Enhanced oversight<\/strong> for vulnerable populations, informed consent, and persistent non-compliance<\/td><\/tr><tr><td><strong>Safety Reporting<\/strong><\/td><td>Basic requirements<\/td><td><strong>Mandatory protocol updates<\/strong> based on emerging safety information<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-enhanced-ethical-oversight-requirements\" class=\"wp-block-heading\">Enhanced Ethical Oversight Requirements<\/h2>\n\n\n\n<h3 id=\"h-informed-consent-standards\" class=\"wp-block-heading\">Informed Consent Standards<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Comprehensibility<\/strong>: Forms must be adequate, complete, and understandable to participants<\/li>\n\n\n\n<li><strong>Ethical Compliance<\/strong>: Must meet rigorous ethics committee review requirements<\/li>\n\n\n\n<li><strong>Dynamic Updates<\/strong>: Sponsors required to revise consent materials as new safety information emerges<\/li>\n\n\n\n<li><strong>Vulnerable Populations<\/strong>: Special protections and additional review requirements for trials involving at-risk groups<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-serious-adverse-event-reporting\" class=\"wp-block-heading\">Serious Adverse Event Reporting<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Principal Investigator Obligation<\/strong>: Mandatory reporting of serious adverse events to ethics committees<\/li>\n\n\n\n<li><strong>Timeline Requirements<\/strong>: Defined reporting windows for different severity classifications<\/li>\n\n\n\n<li><strong>Documentation Standards<\/strong>: Comprehensive record-keeping and follow-up investigation protocols<\/li>\n\n\n\n<li><strong>Escalation Procedures<\/strong>: Clear pathways for addressing persistent non-compliance issues<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-impact-on-clinical-development\" class=\"wp-block-heading\">Strategic Impact on Clinical Development<\/h2>\n\n\n\n<h3 id=\"h-sponsor-responsibilities\" class=\"wp-block-heading\">Sponsor Responsibilities<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Protocol Management<\/strong>: Continuous updating of trial protocols based on safety data<\/li>\n\n\n\n<li><strong>Investigator&#8217;s Brochure<\/strong>: Regular revisions reflecting emerging clinical and safety information<\/li>\n\n\n\n<li><strong>Quality Management<\/strong>: Enhanced systems for monitoring and ensuring GCP compliance across all sites<\/li>\n\n\n\n<li><strong>Risk Mitigation<\/strong>: Proactive identification and management of potential compliance issues<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-principal-investigator-obligations\" class=\"wp-block-heading\">Principal Investigator Obligations<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Site-Level Accountability<\/strong>: Ultimate responsibility for all trial activities conducted at their facility<\/li>\n\n\n\n<li><strong>Team Supervision<\/strong>: Oversight of all delegated tasks performed by site staff<\/li>\n\n\n\n<li><strong>Ethics Coordination<\/strong>: Direct engagement with ethics committees on safety and compliance matters<\/li>\n\n\n\n<li><strong>Participant Protection<\/strong>: Primary duty to ensure participant safety and rights throughout trial duration<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-implications-amp-industry-preparedness\" class=\"wp-block-heading\">Market Implications &amp; Industry Preparedness<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Implementation Timeline<\/strong>: Three-month preparation period (June-September 2026) for industry adaptation<\/li>\n\n\n\n<li><strong>Compliance Investment<\/strong>: Significant resources required for SOP updates, staff training, and system enhancements<\/li>\n\n\n\n<li><strong>Competitive Advantage<\/strong>: Companies with robust GCP infrastructure positioned to maintain development momentum<\/li>\n\n\n\n<li><strong>Global Harmonization<\/strong>: Alignment with ICH-GCP E6(R2) and other international standards facilitates global trial execution<\/li>\n\n\n\n<li><strong>Quality Focus<\/strong>: Shift toward quality-by-design rather than compliance-by-inspection approaches<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This regulatory update represents China&#8217;s commitment to maintaining the highest international standards for clinical trial conduct while ensuring robust protection of research participants and data integrity in the world&#8217;s second-largest pharmaceutical market.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory implementation, compliance requirements, and industry impacts. Actual outcomes may differ due to varying interpretation of guidelines, resource constraints, and evolving regulatory expectations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China&#8217;s National Medical Products Administration (NMPA), National Health Commission (NHC), National Administration of Traditional Chinese&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[60,14],"class_list":["post-67916","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-nhc-nhfpc","tag-nmpa"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China&#039;s Four Health Regulators Issue Revised Good Clinical Practice Guidelines Effective September 2026, Strengthening Trial Oversight and Ethical Standards - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China&#039;s National Medical Products Administration (NMPA), National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control and Prevention Administration jointly released the revised &quot;Announcement on the Good Clinical Practice for Drug Trials,&quot; which will take effect on September 1, 2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67916\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China&#039;s Four Health Regulators Issue Revised Good Clinical Practice Guidelines Effective September 2026, Strengthening Trial Oversight and Ethical Standards\" \/>\n<meta property=\"og:description\" content=\"China&#039;s National Medical Products Administration (NMPA), National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control and Prevention Administration jointly released the revised &quot;Announcement on the Good Clinical Practice for Drug Trials,&quot; which will take effect on September 1, 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67916\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-10T12:40:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-10T12:40:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67916#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67916\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China&#8217;s Four Health Regulators Issue Revised Good Clinical Practice Guidelines Effective September 2026, Strengthening Trial Oversight and Ethical Standards\",\"datePublished\":\"2026-06-10T12:40:24+00:00\",\"dateModified\":\"2026-06-10T12:40:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67916\"},\"wordCount\":515,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"NHC (NHFPC)\",\"NMPA\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67916#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67916\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67916\",\"name\":\"China's Four Health Regulators Issue Revised Good Clinical Practice Guidelines Effective September 2026, Strengthening Trial Oversight and Ethical Standards - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-10T12:40:24+00:00\",\"dateModified\":\"2026-06-10T12:40:25+00:00\",\"description\":\"China's National Medical Products Administration (NMPA), National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control and Prevention Administration jointly released the revised \\\"Announcement on the Good Clinical Practice for Drug Trials,\\\" which will take effect on September 1, 2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67916#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67916\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67916#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China&#8217;s Four Health Regulators Issue Revised Good Clinical Practice Guidelines Effective September 2026, Strengthening Trial Oversight and Ethical Standards\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China's Four Health Regulators Issue Revised Good Clinical Practice Guidelines Effective September 2026, Strengthening Trial Oversight and Ethical Standards - Insight, China&#039;s Pharmaceutical Industry","description":"China's National Medical Products Administration (NMPA), National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control and Prevention Administration jointly released the revised \"Announcement on the Good Clinical Practice for Drug Trials,\" which will take effect on September 1, 2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67916","og_locale":"en_US","og_type":"article","og_title":"China's Four Health Regulators Issue Revised Good Clinical Practice Guidelines Effective September 2026, Strengthening Trial Oversight and Ethical Standards","og_description":"China's National Medical Products Administration (NMPA), National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control and Prevention Administration jointly released the revised \"Announcement on the Good Clinical Practice for Drug Trials,\" which will take effect on September 1, 2026.","og_url":"https:\/\/flcube.com\/?p=67916","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-10T12:40:24+00:00","article_modified_time":"2026-06-10T12:40:25+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67916#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67916"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China&#8217;s Four Health Regulators Issue Revised Good Clinical Practice Guidelines Effective September 2026, Strengthening Trial Oversight and Ethical Standards","datePublished":"2026-06-10T12:40:24+00:00","dateModified":"2026-06-10T12:40:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67916"},"wordCount":515,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["NHC (NHFPC)","NMPA"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67916#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67916","url":"https:\/\/flcube.com\/?p=67916","name":"China's Four Health Regulators Issue Revised Good Clinical Practice Guidelines Effective September 2026, Strengthening Trial Oversight and Ethical Standards - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-10T12:40:24+00:00","dateModified":"2026-06-10T12:40:25+00:00","description":"China's National Medical Products Administration (NMPA), National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control and Prevention Administration jointly released the revised \"Announcement on the Good Clinical Practice for Drug Trials,\" which will take effect on September 1, 2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67916#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67916"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67916#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China&#8217;s Four Health Regulators Issue Revised Good Clinical Practice Guidelines Effective September 2026, Strengthening Trial Oversight and Ethical Standards"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67916","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67916"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67916\/revisions"}],"predecessor-version":[{"id":67918,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67916\/revisions\/67918"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67916"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67916"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67916"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}